APAC Anemia Drugs Market Analysis Report 2022 to 2030

APAC Anemia Drugs Market Analysis

$ 3999

The APAC Anemia drugs market was valued at $3.36 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.17% from 2022 to 2030 and will reach $7.28 Bn in 2030. One of the main reasons propelling the growth of this market is the rising prevalence of chronic kidney disease and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Amgen, Bayer AG, Takeda Pharmaceutical, GlaxoSmithKline, Johnson, and Johnson, Pfizer, and Novartis.

ID: IN10APPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Asia - Pacific AUTHOR: Nandini Shah

Buy Now

APAC Anemia Drugs Market Executive Summary

The APAC Anemia drugs market was valued at $3.36 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.17% from 2022 to 2030 and will reach $7.28 Bn in 2030. Anemia is a medical condition in which the hemoglobin or red blood cell (RBC) count is lower than normal. Fatigue, shortness of breath, dizziness, and palpitations are some of the most frequent signs and symptoms of anemia. Anemia is caused by excessive blood loss, which can occur during delivery, menstruation, or loss of RBCs owing to prolonged bleeding. The market includes drugs used to treat various types of anemia, including iron-deficiency anemia, sickle cell anemia, and aplastic anemia.

The market is driven by a variety of factors, including an increased prevalence of anemia in the region, a growing geriatric population, and the rising prevalence of chronic kidney disease (CKD) and cancer. In addition, the increasing availability of healthcare facilities and the growing adoption of advanced medical technologies are also contributing to the growth of the anemia drugs market in APAC.

Market Dynamics

Market Growth Drivers

Anemia is a widespread condition in the APAC region, affecting Millions of people. The increasing prevalence of anemia, especially in low and middle-income countries, is driving the demand for anemia drugs. The geriatric population in the APAC region is increasing rapidly, and this demographic is at a higher risk of developing anemia. As the aging population grows, the demand for anemia drugs is also expected to increase.

According to Research, by 2050, one in every four individuals in Asia and the Pacific will be over 60. Between 2010 and 2050, the region's population of senior people (those over the age of 60) will treble, reaching about 1.3 billion individuals. CKD is a leading cause of anemia, and its prevalence is increasing in the APAC region due to factors such as aging, urbanization, and changes in lifestyle. This is expected to drive the demand for anemia drugs. In Asia, up to 434.3 Mn persons have CKD, with up to 65.6 Mn having advanced CKD. China (up to 159.8 Mn) and India (up to 140.2 Mn) had the highest number of adults with CKD in the region, accounting for 69.1% of the total number of adults with CKD in the region. The development of innovative therapies, such as erythropoietin-stimulating agents and iron supplements, is driving the growth of the anemia drugs market in the APAC region. These treatments offer improved efficacy, safety, and convenience compared to traditional therapies, driving demand for them. With that Governments in the APAC region are increasing their healthcare spending, and this is expected to boost the availability of anemia drugs, especially in low and middle-income countries.

Market Restraints

There is a lack of awareness about anemia in many parts of the APAC region, especially in rural areas. This can lead to underdiagnosis and undertreatment of the condition. Anemia drugs can be expensive, and this can limit access to treatment, especially in low and middle-income countries. Some anemic medications, such as erythropoietin-stimulating medicines, can cause hypertension, blood clots, and an increased risk of some malignancies. This can limit their use, particularly in patients with underlying health issues. The APAC anemia drug industry is highly competitive, with several businesses producing products that are identical. This might cause pricing pressure and limit the profitability of market enterprises.

Competitive Landscape

Key Players

Amgen
Bayer AG
Takeda Pharmaceutical
GlaxoSmithKline
Johnson and Johnson
Pfizer
Novartis

Healthcare Policies and Regulatory Landscape

The regulatory body for the anemia drugs market varies by country. However, some of the major regulatory bodies that oversee the approval and marketing of anemia drugs include:

The Ministry of Food and Drug Safety (MFDS) is responsible for the evaluation and approval of drugs in South Korea. In India, the Central Drugs Standard Control Organization (CDSCO) oversees the regulation and approval of Drugs in the country. Whereas, The Pharmaceuticals and Medical Devices Agency (PMDA) is responsible for the evaluation and approval of in Japan and the Australian Therapeutic Goods Administration (TGA): The TGA is the regulatory body for the approval and marketing of anemia drugs in Australia.

Reimbursement Scenario

The reimbursement scenario for anemia drugs in the APAC region varies greatly based on the country and the drug in question. Many nations in the region, in general, have national health insurance systems or other forms of government-funded healthcare programs that may reimburse for anemia medications. However, reimbursement rates and requirements vary depending on the medicine and indication. Some countries, for example, may only fund anemia medications for individuals who have certain underlying diseases, such as chronic kidney disease or cancer. In rare situations, the availability of alternative treatments, such as blood transfusions or other non-pharmacological interventions, may also influence reimbursement rates.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anemia Drugs Market Segmentation

By Type (Revenue, USD Bn)

Iron Deficiency
CKD (Chronic Kidney Disease)
Sickle Cell
Aplastic
Others

By Drugs

Dietary Supplements
Medicines

The types of nutritional supplements are further broken down into iron and vitamin supplements, among other categories, whilst the categories of medicines include antibiotics, hormones (erythropoietin), and chelation therapy (lead poisoning), among others.

By Distribution Channel (Revenue, USD Bn)

Hospital Pharmacy
Store Pharmacy
Online
Others

The distribution channel for anemia drugs in APAC is complex and multifaceted. Pharmaceutical companies must work with a variety of stakeholders, including hospital and retail pharmacies, distributors, and regulatory authorities, to ensure that their products are effectively distributed to patients who need them.

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.